2021-002071-19
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria
BAYER AG·EU Clinical Trials RegisterOngoing
Study focus
- Disease/Condition
- Chronic kidney disease
Sponsor & location
- Primary sponsor
- BAYER AG
- Funder
- Bayer AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Mean reduction from baseline to Month 6 in Urinary Protein-to-Creatinine Ratio
ICD-10 classifications
Chronic kidney diseaseChronic kidney disease, unspecifiedChronic kidney disease, stage 1Chronic kidney disease, stage 4Chronic kidney disease, stage 2
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2021-002071-19
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2021-002071-19 through Pure Global AI's free database. This phase not specified trial is sponsored by BAYER AG and is currently Ongoing. The study focuses on Chronic kidney disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.